[comova]

For example, in the recent Phase 2b CB1 agonist for cannabis user disorder from AELIS, the FDA required a standard of efficacy of an 80% reduction in use. The trial failed for unrelated reasons, but many researchers in the field have expressed frustration that this requirement, a reduction far beyond what will improve a patient’s health, sends a negative signal to other companies interested in advancing effective addiction treatments.